FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 06/2022”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the US-Biotech sector.
As of the tip of June 2022, we determine the next present VC traits within the US-Biotech sector:
- In 2022, total Biotech funding within the USA has reached USD 17,996m to this point
- The highest 5 offers exceed USD 270m every, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Enterprise Companions (USA) is main the Prime 5 Buyers (by deal quantity), adopted by OrbiMed (USA) and 8VC (USA)
- Oncology dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink